The supraclavicular brachial plexus block (BPB) is a frequently used anaesthetic method for upper limb surgeries, including distal radial fracture surgery. Adding liposomal bupivacaine to BPB has shown promise in enhancing postoperative pain control. A previous randomized controlled trial demonstrated that it reduced pain scores and OBAS compared to plain bupivacaine alone, especially on postoperative day (POD) 1. Adding adjuncts to non-liposomal local anaesthetics can also enhance and prolong postoperative pain relief. The effectiveness of liposomal bupivacaine compared to adjuncts like dexamethasone and dexmedetomidine remains unclear. Since liposomal bupivacaine is more expensive, it is crucial to compare its analgesic efficacy with these alternatives. A randomized controlled trial comparing liposomal bupivacaine versus dexamethasone in the interscalene BPB for shoulder surgery found that liposomal bupivacaine resulted in statistically significantly lower pain scores and less pain interference in the Brief Pain Inventory, although the reduction was not considered clinically relevant. Its high cost may therefore limit its routine use unless specific clinical contexts where its efficacy is maximized are identified. Notably, patients with risk factors like psychological factors, preoperative pain, and prior analgesic use may benefit most from its application. A randomized controlled trial to compare the analgesic efficacy of liposomal bupivacaine plus plain bupivacaine versus dexamethasone plus plain bupivacaine in supraclavicular BPB for patients at higher risk of poor acute pain control post distal radial fracture surgery will be conducted. Patients with severe preoperative pain, opioid use, depressive symptoms, anxiety symptoms, and/or higher energy and high-grade fracture cases will be selected. The primary outcome measured is the intensity of acute postoperative pain with movement in the first 48 hours after surgery. Important secondary outcomes include pain intensity at rest, opioid consumption, OBAS scores, chronic pain, and upper limb functionality.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
90
10ml 0.5% plain bupivacaine plus 10ml 1.33% liposomal bupivacaine (133mg)
19ml 0.5% plain bupivacaine plus 1ml (4mg) dexamethasone
Queen Mary Hospital
Hong Kong, Hong Kong
RECRUITINGWeighted area under curve (AUC) pain score with movement
The weighted area under curve (AUC) numerical rating scale (NRS) pain score with movement (active wrist flexion and extension) from 0-48 hours after distal radial fracture surgery.
Time frame: The first 48 hours after surgery
NRS pain scores
NRS pain scores both at rest and with movement will be assessed from after surgery to POD 7. (NRS scale 0-10, where 0 is no pain, and 10 is the worst possible pain)
Time frame: Postoperative day 0-7
Overall Benefit of Analgesic Score (OBAS)
Overall Benefit of Analgesic Score (OBAS) will be assessed once a day until POD 7 (range, 0 \[best\] to 28 \[worst\]).
Time frame: Postoperative day 0-7
Acute postoperative opioid consumption
The daily consumption of oxycodone in the ward and after discharge will be recorded. The dose of rescue intravenous morphine consumption in the PACU will also be recorded.
Time frame: Postoperative day0-7
Sleep disturbance
Sleep disturbance due to pain will be evaluated once a day till POD 7 (0-10, where 0 represents no disturbance and 10 represents the most disturbance possible).
Time frame: Postoperative day0-7
Quality of recovery (QoR)
This will be accessed using the Quality of recovery (QoR) questionnaire. (range from 0 to 18, where 0 represent the worst quality of recovery and 18 represent the best quality of recovery)
Time frame: Postoperative day0-7
Adverse effects related to supraclavicular BPB
The potential side effects related to the supraclavicular BPB will be recorded.
Time frame: postoperative day0-2
Opioid related side effects
Opioid related side effects will be recorded.
Time frame: postoperative day0-7
Analgesic block duration.
Time to return of pain, time to sensory resolution, time to motor resolution will be recorded on POD 1.
Time frame: On postoperative day1
Sensory and motor assessment of the affected upper limb
Sensation to pin prick will be tested over the following areas: C5 (lateral shoulder), C6 (thumb), C7 (3rd finger), and C8 (4th finger) dermatomes. Motor assessment will be done by recording grip strength and bicep contraction. Sensation will be rated as 0-10 , where 0 represent no sensation and 10 represent normal sensation. Motor function will be rated as 0 (paralysis), 1 (paresis), 2 (normal power).
Time frame: Postoperative day0-1
Health related quality of life
Health related quality of life will be assessed using the SF-12v2. Baseline scores will be obtained before surgery. The SF-12v2 will produce two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Both summary scores range from 0 to 100, where higher scores always indicate better physical and mental health.
Time frame: Baseline and at 3, 6 and 12 weeks after surgery
Upper limb functional scores.
The validated Chinese versions of the Disabilities of the Arm, Shoulder, and Hand (QuickDASH) will be used to assess upper limb functional scores. Baseline scores will be obtained before surgery. (Range from 0 to 100, a lower score indicates a better outcome)
Time frame: Baseline and at 3, 6 and 12 weeks after surgery
Hand grip power of normal and injured side
Hand grip power of normal and injured side will be assessed (both hands).
Time frame: At 3, 6 and 12 weeks after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.